Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma - Test2 - elhamkhani - TriplyDB

Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma

Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma

http://www.wikidata.org/entity/Q27027762

about

Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma Update and Review on the Surgical Management of Primary Cutaneous Melanoma Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications Weighing the value of completion nodal dissection for melanoma.Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol.Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.State of melanoma: an historic overview of a field in transition.Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence.Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report.Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: A retrospective study of surveillance, epidemiology, and end-result population-based data.Videoscopic inguinal lymphadenectomy for metastatic melanoma.Sentinel lymph node biopsy in melanoma: controversies and current guidelines.Sentinel lymph node biopsy for cutaneous head and neck malignancies.The natural history of thin melanoma and the utility of sentinel lymph node biopsy.Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study.Sentinel lymph node biopsy plus wide local excision vs. wide location excision alone for primary cutaneous melanoma: a systematic review and meta-analysis.Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma.Sentinel lymph node biopsy in melanoma: final results of MSLT-I.Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan.Epidemiology, management and survival outcomes of primary cutaneous melanoma: a ten-year overview.Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute.Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases.Lymph node retrieval rates in melanoma: a quality assessment parameter.Evaluation of sentinel node biopsy for cutaneous squamous cell carcinoma.Sentinel node biopsy (SNB) in malignant melanoma as same day procedure vs delayed procedure: clinical and economic outcome.Population-Based Analysis of Completion Lymphadenectomy in Intermediate-Thickness Melanoma.The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis.Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin.The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy.Improvement and persistent disparities in completion lymph node dissection: Lessons from the National Cancer Database.Impact of extended lymphadenectomy on morbidity and regional recurrence-free survival in melanoma patients.Use of indirect lymphography to identify sentinel lymph node in dogs: a pilot study in 30 tumours.Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures.Validation of a nomogram predicting sentinel lymph node status in melanoma in an Irish population.

P2860

Q24187945-BDB2E43F-D51B-4F05-BCBC-9DFB8AB949DC Q26851966-66E4AA75-AFEE-4CC2-A895-F94C740409F7 Q26996059-A81AB8AC-F24B-4730-ADE1-0BF29E28F13D Q30248851-CA15AD63-8FAD-442C-AAC8-D819335851CB Q33556234-30E4B63C-1F31-4300-BD42-ECC5EF75D87D Q33605879-D47A72C0-E0F6-4B12-9883-68B3DB63F1E4 Q33693906-EB7448D1-4650-43EE-B9A6-DF2DEEA9E78C Q34235463-DC96287F-B11D-44D5-A2EB-CFD82EC21A3E Q34464461-A50C0F85-70D1-4C11-ABB5-2F7A00CA4E1A Q36061720-8ECAA28C-2F78-4606-8D3F-6096ECC1DAA4 Q38146705-251DD570-46F0-4702-9280-98381F445049 Q38190113-5FADCF0E-7460-4C4C-AB5D-DF8AB5730CFC Q38286125-22FE61D0-A73E-4CF3-BA63-CDCAEE762051 Q38675788-54F0EE13-F2FC-472E-A2C5-79B6AF62EE8D Q38683103-A1EFEA12-6F45-4073-B7B7-7A7BFECE8B35 Q38784286-DAA8C8A3-C1DB-41FF-AFFA-4CDA56B0171C Q38945950-9B83F87B-02F6-40AB-B359-95B02C4180F4 Q38951984-685089B6-EC72-473C-BE37-A49705AAA645 Q39173175-DFE1CD6D-CF1A-4FE2-93C8-437123D176A3 Q39200194-0205EA2E-1E1D-4894-BD94-6F2CC7D29514 Q40520492-70599C04-1AE7-488C-BE03-2AC1E8E3E82D Q40835747-074640EB-FCE4-40B6-BA75-4F8A403FA02D Q40922293-9844772F-4839-4326-97A0-8788833F5A55 Q41559537-43378AEB-C802-4A2C-8BED-9366D272661D Q43878247-DA1D77CF-02A4-4C99-8321-C54C78E26CC3 Q44575561-72C8AFEF-A2BD-4D21-A3CB-A402160884C6 Q44624442-BA5B50B4-2C56-4396-8898-3D713947DA70 Q44857485-841BABC8-27F8-4099-896C-EF2B54D912AC Q47669815-A0E1B2C3-CC27-4846-9A9D-60EC0301D54E Q47692272-83C17125-582C-460C-B5C4-1B17F69A4FD1 Q48348150-1D7BAC2E-C2E3-4D98-B667-0C3A979337DD Q48369437-DF60D081-916A-4478-9256-23EDC9C10654 Q50204442-B010554E-7D26-4AE4-B648-A7B22509E2F9 Q50241634-B1021618-BBB8-42F8-A957-8933464FFC19 Q50453427-9D7E713D-37E2-413E-A778-6347CB4637A3

P2860

Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma

http://www.wikidata.org/entity/Q27027762

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@ast

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@en

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@nl

type

label

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@ast

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@en

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@nl

prefLabel

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@ast

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@en

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@nl

P1433

Q27027762-7FBA9B12-618E-4D5F-80CE-61AA96411680

P1476

Q27027762-374974FC-5608-4469-811A-ABE5DC6140C5

P2093

Q27027762-538527EF-A68B-420C-9389-432F8085AD47

P2860

Q27027762-07BCAA33-22D7-4853-8706-9FCA11B27763

Q27027762-1D32FF3B-5861-467D-9341-99613BDCAAFB

Q27027762-425723B8-1959-4ACD-B6BA-170489EB2DF5

Q27027762-71CD4F54-53D4-4832-A415-27A94B8CB7B6

Q27027762-84B6AE7C-AB2F-442D-B056-C8D67FE6C387

Q27027762-AF8E1817-5A5A-40DA-AFE4-80BA1F0CAFF1

Q27027762-EBDBE84C-DA1B-490D-8D25-690006CC6521

Q27027762-EC324CFD-6B89-4C4C-98A6-41B02A237AD1

Q27027762-F126BBC2-14BC-4851-BBFA-F704DCDF1527

P2888

Q27027762-C7508578-89E2-4A23-BE20-3F37F7CC98F8

P304

Q27027762-6DDA9E7F-E4EE-4C9F-91BF-73D0BC027268

P31

Q27027762-EC456A5D-EE5B-4ADA-A852-9DC51E048EDC

P3181

Q27027762-C326E945-528A-47D9-A103-572ECF156FD8

P356

Q27027762-4D11ED81-8B77-4F5B-B8F2-07EE20347940

P407

Q27027762-D5075756-85EE-4653-BD20-E214FE082578

P433

Q27027762-587B2F43-B7DA-49F8-B3BB-148F7FCDC69E

P478

Q27027762-B8E35C14-0B5B-4214-BD2F-F7BF42C60A3A

P577

Q27027762-76390CF5-6AA7-4D17-AC8D-EB743E7A36C9

P6179

Q27027762-DC8015A3-79C6-41AE-BED9-E00DD7DE54A9

P698

Q27027762-1B40CD8B-A7C1-4B36-8361-7F25BF45C4E1

P921

Q27027762-1C977FBD-AD83-4EAF-9E85-528E4475BB2D

Q27027762-744907D6-C12B-41AF-B1CB-983715D49C41

Q27027762-BA5DD0E4-DAAD-4433-B552-757E60328BD7

P932

Q27027762-DD5AC881-E96C-4B27-92CA-19AC5EA660E0

P3181

P356

S10585-012-9503-3

P1433

Clinical & Experimental Metastasis

P1476

Overview and update of the pha ...... SLT-I and MSLT-II) in melanoma

@en

P2093

Donald L. Morton

http://www.w3.org/2001/XMLSchema#string

P2860

Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).

Sentinel-node biopsy or nodal observation in melanoma.

Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.

Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node.

Lymphatic drainage of skin to a sentinel lymph node in a feline model.

Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

P2888

s10585-012-9503-3

P304

699-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4765490

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S10585-012-9503-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020167650

http://www.w3.org/2001/XMLSchema#string

P698

22729520

http://www.w3.org/2001/XMLSchema#string

P921

lymphadenectomy

phase III clinical trial

multicenter trial

P932

3463679

http://www.w3.org/2001/XMLSchema#string